Share Name Share Symbol Market Type Share ISIN Share Description
BTG Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -0.09% 573.00p 572.50p 573.50p 575.50p 567.50p 573.00p 130,226.00 12:51:11
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 447.5 57.5 15.8 36.3 2,206.78

BTG Share Discussion Threads

Showing 4451 to 4468 of 4475 messages
Chat Pages: 179  178  177  176  175  174  173  172  171  170  169  168  Older
DateSubjectAuthorDiscuss
24/3/2017
15:06
Indeed,suggests to my mind that they're going to issue another self congratulatory update that has little cognisance to the likely disappointment of the market .Expectations are being badly managed by the company which has the audacity to applaud itself for not paying a dividend!
steeplejack
24/3/2017
11:58
bounced off downtrend resistance and looks to be continuing the downtrend sold! woody
woodcutter
24/3/2017
10:08
Two weeks to go to the closed period update...two weeks of trader pessimism.Then fgs, let's hope for a glowing report across the group and NO nasty surprises!Dum spiro.....
fhmktg
23/3/2017
07:40
From eye eye eye Anti-Venom Market is projected to reach USD 1493.2 million by 2021, at a CAGR of 6.12%. Press release from: Market Data Forecast According to the report Global Anti-Venom Market, published by Market Data Forecast, the global market is projected to reach USD 1493.2 million by 2021, at a CAGR of 6.12% from 2016 to 2021. For full report refer to www.marketdataforecast.com/market-reports/global-antiveno... Anti-venom is the organic product that detoxifies poisoning of fatal bites and stings. It is prepared from the milking venom of toxic animals such as snakes, spiders, scorpions, and other poisonous animals. Anti-venom is also known as “venom antiserum” and “anti-venom immunoglobulin. It is evaluated that, approximately 100,000 people die worldwide with snake bites annually. To vanquish poisonous effects after venomous bites, Anti-venom products are emerged including vaccines and hyper immune sera. Free sample for the report is available at www.marketdataforecast.com/market-reports/global-antiveno... The prime factors that are compelling the expansion of the market are increase in the government initiations to promote the progress of high quality anti-venom products, existence of highest number of snake bite victims and appraise pipeline products launch. Additionally, advancement of deaths from venomous animal’s bites and inclining research to merge advanced anti-venom products is further stimulating the growth of Anti-venom Market. The key restraints of Anti-venom market are withdrawal of anti-venom products, insufficient funding to enlarge the anti-venom products to meet demand, high cost of the products, regulatory entanglements, and high costs of maintaining livestock for anti-venom. Avail discount at www.marketdataforecast.com/market-reports/global-antiveno... By Antivenom • Monovalent • Bivalent • Trivalent • Tetravalent • Polyvalent By Hyperimmune sera • Homologous • Heterologous By Animal • Snakes • Scorpions • Spiders • Others By Geography • North America Anti-venom Market • Europe Anti-venom Market • Asia-Pacific Anti-venom Market • Latin America Anti-venom Market • Middle-East & Africa Anti-venom Market Enquire more about the report at www.marketdataforecast.com/market-reports/global-antiveno... The key competitors in the Anti-Venom market are Instituto Bioclon, S.A. de C.V. (Mexico), Pfizer AG (Switzerland), CSL Limited (Australia), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), Rare Disease Therapeutics, Inc. (U.S.), Vins Bio products Limited (India), BTG Plc (U.K.), Incepta Vaccine Ltd. (Bangladesh), and Bharat Serum and Vaccines Limited (BSV) (India). Buy now www.marketdataforecast.com/cart/buy-now/global-antivenom-... FIO CIAO Paulo
bargainbob
22/3/2017
17:12
Sell off today was done by selling programm . Who was behind this programm shortsellers or just sellers I dont know. Broker told that trades were automated by robot. Dame Louis doesn't want protect her shareholders imo
a1ord53
22/3/2017
08:42
Mark my words, because I know about these things (touching side of nose), it is Varithena, and only Varithena, that is causing markets all over the world to drop steeply. Trump's inability to get his health insurance changes through is merely the fart on the edge of the thunderstorm. LOL
harijan
21/3/2017
16:33
I'd be very surprised if Varithena was to surprise for the better if the recent price movement is anything to go by.
steeplejack
21/3/2017
14:06
Presumably the shorters will push the share price down for the next two weeks anticipating poor news on Varithena?
fhmktg
21/3/2017
13:16
This chart sucks! Hopefully next weeks results can lead to a breakout,as has happened to Ventura this morning.
dp1umb
21/3/2017
12:43
Does Louise know how boring it is on this thread.
bargainbob
21/3/2017
12:40
oh what a lovely bunch of coconuts
bargainbob
21/3/2017
10:02
Oh what a lovely war ?
steeplejack
17/3/2017
16:01
Cannot wait , hope the trading update is a Oh My and not a Oh God.
bargainbob
17/3/2017
15:29
oh (sing along if you know the words)
revoman
17/3/2017
10:21
Trading update due Thursday,6 April.Final results due Tuesday 16th May.
steeplejack
16/3/2017
19:39
Sorry - the name's Bond.
matthu
13/3/2017
17:21
Thanks , was just thinking to myself must have missed Wellbutrin. Sorry for sounding negative in the above , but wishing to see a good set of results before we should be announcing a screaming buy at these levels.
bargainbob
13/3/2017
08:24
Sorry that should have been Vistogard, not Wellbutrin!
fhmktg
Chat Pages: 179  178  177  176  175  174  173  172  171  170  169  168  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170328 12:06:52